369 related articles for article (PubMed ID: 29408820)
1. Heterogeneity of Thyroid Cancer.
Chmielik E; Rusinek D; Oczko-Wojciechowska M; Jarzab M; Krajewska J; Czarniecka A; Jarzab B
Pathobiology; 2018; 85(1-2):117-129. PubMed ID: 29408820
[TBL] [Abstract][Full Text] [Related]
2. The role of microRNAs in thyroid carcinomas.
Forte S; La Rosa C; Pecce V; Rosignolo F; Memeo L
Anticancer Res; 2015 Apr; 35(4):2037-47. PubMed ID: 25862858
[TBL] [Abstract][Full Text] [Related]
3. Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.
de la Fouchardiere C; Oussaid N; Derbel O; Decaussin-Petrucci M; Fondrevelle ME; Wang Q; Bringuier PP; Bournaud-Salinas C; Peix JL; Lifante JC; Giraudet AL; Lopez J; Borson-Chazot F
Target Oncol; 2016 Feb; 11(1):71-82. PubMed ID: 26285789
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathology of thyroid tumours of follicular cells: a review of genetic alterations and their clinicopathological relevance.
Acquaviva G; Visani M; Repaci A; Rhoden KJ; de Biase D; Pession A; Giovanni T
Histopathology; 2018 Jan; 72(1):6-31. PubMed ID: 29239040
[TBL] [Abstract][Full Text] [Related]
5. ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome.
Tavares C; Melo M; Cameselle-Teijeiro JM; Soares P; Sobrinho-Simões M
Eur J Endocrinol; 2016 Apr; 174(4):R117-26. PubMed ID: 26510840
[TBL] [Abstract][Full Text] [Related]
6. How to define follicular thyroid carcinoma?
Schmid KW; Farid NR
Virchows Arch; 2006 Apr; 448(4):385-93. PubMed ID: 16506015
[TBL] [Abstract][Full Text] [Related]
7. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
[TBL] [Abstract][Full Text] [Related]
9. [Genetic factors predisposing to the development of papillary thyroid cancer].
Puzianowska-Kuźnicka M; Pietrzak M
Endokrynol Pol; 2005; 56(3):339-45. PubMed ID: 16350729
[TBL] [Abstract][Full Text] [Related]
10. Poorly Differentiated and Undifferentiated Thyroid Carcinomas.
Eloy C; Ferreira L; Salgado C; Soares P; Sobrinho-Simões M
Turk Patoloji Derg; 2015; 31 Suppl 1():48-59. PubMed ID: 26177317
[TBL] [Abstract][Full Text] [Related]
11. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
13. RAS mutations in thyroid cancer.
Howell GM; Hodak SP; Yip L
Oncologist; 2013; 18(8):926-32. PubMed ID: 23873720
[TBL] [Abstract][Full Text] [Related]
14. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
15. [BRAF initiating mutations in the papillary thyroid carcinoma].
Rusinek D; Gubała E
Endokrynol Pol; 2006; 57(4):438-44. PubMed ID: 17006850
[TBL] [Abstract][Full Text] [Related]
16. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
17. [Pathological and clinical features of malignant thyroid tumors: classification, immunohistology, prognostic criteria].
Schröder S
Veroff Pathol; 1988; 130():1-159. PubMed ID: 3213226
[TBL] [Abstract][Full Text] [Related]
18. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.
Kim TY; Kim WB; Song JY; Rhee YS; Gong G; Cho YM; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2005 Nov; 63(5):588-93. PubMed ID: 16268813
[TBL] [Abstract][Full Text] [Related]
19. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Smith N; Nucera C
J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
[TBL] [Abstract][Full Text] [Related]
20. Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes.
Penna GC; Vaisman F; Vaisman M; Sobrinho-Simões M; Soares P
Cytogenet Genome Res; 2016; 150(3-4):194-207. PubMed ID: 28231576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
